Jazz Pharmaceuticals (JAZZ) and Harmony Biosciences (HRMY) have emerged as notable players in the neuroscience space, especially in the sleep disorder segment. Jazz Pharmaceuticals markets multiple neuroscience drugs, including the blockbuster oral sleep disorder drug Xywav and the cannabidiol (CBD) drug Epidiolex. Harmony Biosciences has only one marketed drug in its portfolio, Wakix (pitolisant), which is approved to treat excessive daytime sleepiness (EDS) or cataplexy in narcolepsy patients. Both compan ...

文章核心观点 - 特朗普自竞选以来转向支持大麻立场，奥驰亚集团（NYSE: MO）将从这一发展中大幅受益 [1] 公司相关 - Aseity Research将高收益收入投资与科技驱动增长相结合，提供股票、ETF、CEF和期权策略的可行见解，利用股息和基于theta的策略实现稳定收入和强劲回报 [1]